Avanafil

Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.

Map view:

Zoom: 100%

More settings

Connection length 100% Label size 100% Node size 100% Line width 100% Label width 100%

Export map as:

Avanafil topic overview

The analysis highlights Art, Adverse effects and Overview as prominent areas in the source structure around Avanafil.

Related topics: 20
Source areas: 4
Connected nodes: 24
Extracted relationships: 30
Related term clusters: 14
Bridge connections: 24

What this topic covers Research coverage

Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.

Overview · 12 topics

Adverse effects · 5 topics

Mechanism of action · 2 topics

Synthesis · 1 topics

Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.

Key facts & relationships

High-confidence facts extracted from structured source data. Use them as anchors for further research.

3D model (JSmol): Interactive image
AHFS/Drugs.com: Monograph
ATC code: G04BE10 (WHO)
CAS Number: 330784-47-9 Y
ChEBI: CHEBI:66876
ChEMBL: ChEMBL1963681 N

Start with your topic. Discover where to go next.

Explore different angles and find fresh ideas to shape your next piece of content.

Avanafil

5PDE5 inhibitor · Erectile dysfunction · FDA

7Phosphodiesterase · Corpus cavernosum penis · Sildenafil

8Headache · Flushing (physiology) · Nasopharyngitis

Explore all related topics Closing gaps

Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.

Overview

Adverse effects

Mechanism of action

Synthesis

Pyrimidine

For the semantics nerds

You can skip this section if you’re here for content ideas and keyword inspiration.

Advanced semantic analysis

How Avanafil connects Entity context

The extracted context around Avanafil shows recurring relationship patterns in the source. For example, Avanafil → AU: S4 (Prescription only), EU: Rx-only, UK: POM (Prescription only), US: ℞-only Another extracted example is Avanafil → EU EMA: by INN, US DailyMed: Avanafil, US FDA: Avanafil. Use these groups to spot repeated connection types before inspecting the individual relationships.

Top relations

Legal status · 4

Avanafil → AU: S4 (Prescription only), EU: Rx-only, UK: POM (Prescription only), US: ℞-only

License data · 3

Avanafil → EU EMA: by INN, US DailyMed: Avanafil, US FDA: Avanafil

3D model (JSmol) · 1

Avanafil → Interactive image

AHFS/Drugs.com · 1

Avanafil → Monograph

ATC code · 1

Avanafil → G04BE10 (WHO)

CAS Number · 1

Avanafil → 330784-47-9 Y

ChEBI · 1

Avanafil → CHEBI:66876

ChEMBL · 1

Avanafil → ChEMBL1963681 N

ChemSpider · 1

Avanafil → 8045620 Y

CompTox Dashboard (EPA) · 1

Avanafil → DTXSID50186727

Important terminology

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

pde5 action fda spedra within minutes ema adverse effects inhibitor 27 names stendra co drugs erectile dysfunction penis sexual mechanism

Avanafil relationships Subject–Predicate–Object triples

TTTA extracted 30 structured relationships around Avanafil. Examples in this analysis include Avanafil → 3D model (JSmol) → Interactive image and Avanafil → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.

Subject	Predicate	Object	Confidence	Src
Avanafil	3D model (JSmol)	Interactive image	1.00	infobox
Avanafil	AHFS/Drugs.com	Monograph	1.00	infobox
Avanafil	ATC code	G04BE10 (WHO)	1.00	infobox
Avanafil	CAS Number	330784-47-9 Y	1.00	infobox
Avanafil	ChEBI	CHEBI:66876	1.00	infobox
Avanafil	ChEMBL	ChEMBL1963681 N	1.00	infobox
Avanafil	ChemSpider	8045620 Y	1.00	infobox
Avanafil	CompTox Dashboard (EPA)	DTXSID50186727	1.00	infobox
Avanafil	DrugBank	DB06237 Y	1.00	infobox
Avanafil	Formula	C23H26ClN7O3	1.00	infobox
Avanafil	IUPHAR/BPS	7448	1.00	infobox
Avanafil	KEGG	D03217 Y	1.00	infobox
Avanafil	Legal status	AU: S4 (Prescription only)	1.00	infobox
Avanafil	Legal status	UK: POM (Prescription only)	1.00	infobox
Avanafil	Legal status	US: ℞-only	1.00	infobox
Avanafil	Legal status	EU: Rx-only	1.00	infobox
Avanafil	License data	EU EMA: by INN	1.00	infobox
Avanafil	License data	US DailyMed: Avanafil	1.00	infobox
Avanafil	License data	US FDA: Avanafil	1.00	infobox
Avanafil	MedlinePlus	a614010	1.00	infobox
Avanafil	Molar mass	483.96 g·mol−1	1.00	infobox
Avanafil	PDB ligand	E6L (PDBe, RCSB PDB)	1.00	infobox
Avanafil	PubChem CID	9869929	1.00	infobox
Avanafil	Routes of administration	By mouth	1.00	infobox
Avanafil	Trade names	Stendra	1.00	infobox
Avanafil	UNII	DR5S136IVO	1.00	infobox
Avanafil	is a	PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27	0.90	text

Related concept clusters Related term clusters

The concept neighborhoods around Avanafil bring nearby vocabulary together. In this analysis, examples include Pde5, Dysfunction and Ema. Use the clusters to find adjacent concepts and terminology that may deserve separate research.

Avanafil
- Pde5
- Dysfunction
- Ema
- Erectile
- Fda
- Inhibitor
- Names
- Stendra
- Action
- Adverse
- Effects
- Approved
avanafil
- Pde5
- Dysfunction
- Ema
- Erectile
- Fda
- Inhibitor
- Names
- Stendra
- Action
- Adverse
- Effects
- Approved
erectile dysfunction
- Dysfunction
- Ema
- Erectile
- Fda
- Inhibitor
- Pde5
- June
- Co
- Drugs
- Mechanism
- Names
- Stendra
onset of action
- Mechanism
- Pde5
- Co
- Drugs
- Dysfunction
- Ema
- Erectile
- Fda
- Inhibitor
- Names
- Sexual
- Stendra
adverse effects
- Effects
- Co
- Drugs
- Dysfunction
- Ema
- Erectile
- Fda
- Inhibitor
- Mechanism
- Names
- Occur
- Stendra
mechanism of action
- Mechanism
- Pde5
- Names
- Sexual
- Stendra
- Co
- Drugs
- Dysfunction
- Ema
- Erectile
- Fda
- Inhibitor
pde5 inhibitor
- Dysfunction
- Ema
- Erectile
- Fda
- Pde5
- June
- Co
- Drugs
- Mechanism
- Names
- Stendra
- Action
fda
- Ema
- Inhibitor
- Pde5
- June
- Co
- Drugs
- Mechanism
- Names
- Stendra
- Action
- Adverse
- Effects

Connections between topic areas Semantic bridges

For Avanafil, one of the stronger structural bridges in this analysis connects Avanafil with Overview. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.

Min side: 3

Avanafil — Overview · splits 12 ⟂ 13

Avanafil — Adverse effects · splits 19 ⟂ 6

Avanafil — Mechanism of action · splits 22 ⟂ 3

Map overview Semantic statistics

Avanafil

Nodes25

Edges24

Triples30

Avg. degree1.92

Density0.08

Components1

Source & methodology

TTTA analyzes the structure around Avanafil to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Art, Adverse effects & Overview, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.

Source: Wikipedia — Avanafil · EN edition · Analysis: TopicsToTalkAbout

Avanafil: Art, Adverse effects & Overview

Avanafil topic overview

What this topic covers Research coverage

Key facts & relationships

Start with your topic. Discover where to go next.

Questions to explore

Explore all related topics Closing gaps

Overview

Adverse effects

Mechanism of action

Synthesis

For the semantics nerds

Advanced semantic analysis

How Avanafil connects Entity context

Avanafil

Top relations

Important terminology

Important terminology

Avanafil relationships Subject–Predicate–Object triples

Related concept clusters Related term clusters

Connections between topic areas Semantic bridges

Map overview Semantic statistics

Avanafil

Source & methodology